EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study

Julie Charles, Aude Belbezier iD, Stéphane Mouret iD, Brigitte Dreno iD, Stéphane Dalle, Céleste Lebbe, Ewa Hainaut-Wierzbicka, Andreea Stefan, Julie de Quatrebarbes, Olivier Dereure, Ouidad Zehou iD, Sandrine Mansard und 12 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72295 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2026. Verfasst von Julie Charles und 23 weiteren Autor:innen. Beteiligte Einrichtung: French Network of Rare Skin Cancers, CARADERM, France. Hauptthemen laut MEDLINE: Somatostatin, Carcinoma, Merkel Cell, Peptides, Cyclic, Skin Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC. To test this hypothesis, we conducted a Phase II, non‐randomized, open trial investigating lanreotide in MCC patients with advanced disease ( ClinicalTrials.gov identifier: NCT02351128).

Methods

Patients with Stage IIIB‐IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR) (defined as the proportion of patients with complete response, partial response, and stable disease) at 3 months. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), somatostatin receptor (SSTR) tumor expression, and treatment safety.

Results

Between April, 2015, and November, 2016, 35 patients received lanreotide, with 12 evaluable at 3 months. The DCR at 3 months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort. Statistical analyses showed no significant difference from the expected 20% response rate ( p = 0.205 for intention‐to‐treat; p = 0.939 for per‐protocol). Kaplan–Meier analysis revealed median OS and PFS of 3.1 months (95% CI, 2–5.5) and 3.5 months (95% CI, 2.3–5.5), respectively. SSTR tumor expression did not correlate with treatment response.

Conclusion

Although limited by its implementation before the era of immunotherapy, this non‐randomized study shows the limited effectiveness of lanreotide as monotherapy in treating patients with advanced MCC. Trial Registration Identifier: NCT02351128

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SomatostatinCarcinoma, Merkel CellPeptides, CyclicSkin NeoplasmsHumansFemaleMaleAgedAged, 80 and overMiddle AgedProspective StudiesTreatment OutcomeNeoplasm StagingReceptors, Somatostatin

Stichwörter der Autor:innen

Merkel cell carcinomadermatologysomatostatintumors

Substanzen

SomatostatinlanreotidePeptides, CyclicReceptors, Somatostatin

Autor:innen und Institutionen

  • French Network of Rare Skin Cancers, CARADERM, France.
  • Dermatology, Allergology and Photobiology Department - CHU Grenoble Alpes, Univ. Grenoble Alpes, Grenoble, France.
  • Dermatology Department, CHU de Nantes, Nantes, France.
  • Dermatology Department, Hospices Civils de Lyon, Pierre-Bénite, France.
  • AP-HP Dermato-Oncology and CIC, Cancer Institute APHP. Nord Paris cité, INSERM U1342-Equipe 1-CNRS EMR8000, Saint Louis Hospital, Université Paris Cite, Paris, France.
  • Dermatology Department, CHU de Poitiers, Poitiers, France.

ORCID-Profile: Aude Belbezier, Stéphane Mouret, Brigitte Dreno, Ouidad Zehou, Alain Dupuy, Caroline Gaudy-Marqueste, Henri Montaudié, Jean-Philippe Arnault, Thibault Kervarrec, Jean-Louis Quesada

Zitieren

APA

Charles, J., Belbezier, A., Mouret, S., Dreno, B., Dalle, S., Lebbe, C., Hainaut-Wierzbicka, E., Stefan, A., de Quatrebarbes, J., Dereure, O., Zehou, O., Mansard, S., Dupuy, A., Dutriaux, C., Grange, F., Gaudy-Marqueste, C., Montaudié, H., Arnault, J. P., Le Corre, Y., …, & Group of Cutaneous Oncology of the French Society of Dermatology (2026). Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study. Cancer Medicine. https://doi.org/10.1002/cam4.72295

Vancouver

Charles J, Belbezier A, Mouret S, Dreno B, Dalle S, Lebbe C, et al. Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study. Cancer Medicine. 2026. doi:10.1002/cam4.72295

BibTeX
@article{Charles2026,
  author = {Charles, Julie and Belbezier, Aude and Mouret, Stéphane and Dreno, Brigitte and Dalle, Stéphane and Lebbe, Céleste and Hainaut-Wierzbicka, Ewa and Stefan, Andreea and de Quatrebarbes, Julie and Dereure, Olivier and Zehou, Ouidad and Mansard, Sandrine and Dupuy, Alain and Dutriaux, Caroline and Grange, Florent and Gaudy-Marqueste, Caroline and Montaudié, Henri and Arnault, Jean-Philippe and Le Corre, Yannick and Kervarrec, Thibault and Quesada, Jean-Louis and Samimi, Mahtab and Leccia, Marie-Thérèse and Group of Cutaneous Oncology of the French Society of Dermatology, Group of Cutaneous Oncology of the French Society of Dermatology},
  title = {Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72295}
}
Kostenlos starten →